Delivery Order SPE2DB22D1017-SPE2DB25FG3NL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 620 mcg/2.48 ml pharmaceutical product, with a ceiling value of $4,745.38. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of April 30, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its...
- The Defense Logistics Agency awarded a $4,420.77 delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 MCG/2.24 ML on September 29, 2025, with completion targeted for September 30, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office...
- The Defense Logistics Agency (DLA) awarded a $1,633.20 delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Teriparatide 560mcg/2.24mL pen injections. This firm fixed-price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,422.77 to AmerisourceBergen Drug Corp for Teriparatide 560 MCG/2.24 ML pen injections on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $3,019.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Teriparatide 560 mcg/2.24 mL pens, with an ultimate completion date of November 21, 2025. This non-set-aside competitive award was issued on November 20, 2025, and represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,569.17 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24mL pens on June 4, 2025, with an ultimate completion date of June 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,286.27 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24ml pens on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Teriparatide 560 mcg/2.24 ml pen injections, with a ceiling value of $6,041.57 and a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The pharmaceutical will be supplied to the place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections, valued at $22,413.75 under a firm fixed-price contract. The award was made on May 27, 2025, with an ultimate completion date of May 28, 2025, and represents a competitive, non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $26,852.75 delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of June 3, 2025, and was competitively awarded without set-aside provisions. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Teriparatide is a recombinant human parathyroid hormone used in...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG3NLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 620 mcg/2.48 mL in the amount of $8,235.06. The contract was awarded on May 27, 2025, with an ultimate completion date of May 28, 2025, and utilizes firm fixed price pricing with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support military and veteran healthcare systems. Teriparatide is an injectable medication used in osteoporosis treatment, reflecting the company's role in providing specialized pharmaceutical products across multiple therapeutic domains to federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 5/27/25 |